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Abstract
Chronic kidney disease (CKD) is an increasingly prevalent condition globally and is strongly associated with incident car-
diovascular disease (CVD). Hypertension is both a cause and effect of CKD and affects the vast majority of CKD patients. 
Control of hypertension is important in those with CKD as it leads to slowing of disease progression as well as reduced 
CVD risk. Existing guidelines do not offer a consensus on optimal blood pressure (BP) targets. Therefore, an understand-
ing of the evidence used to create these guidelines is vital when considering how best to manage individual patients. Non-
pharmacological interventions are useful in reducing BP in CKD but are rarely sufficient to control BP adequately. Patients 
with CKD and hypertension will often require a combination of antihypertensive medications to achieve target BP. Certain 
pharmacological therapies provide additional BP-independent renoprotective and/or cardioprotective action and this must be 
considered when instituting therapy. Managing hypertension in the context of haemodialysis and following kidney transplan-
tation presents further challenges. Novel therapies may enhance treatment in the near future. Importantly, a personalised and 
evidence-based management plan remains key to achieving BP targets, reducing CVD risk and slowing progression of CKD.
Key Points 
Controlling hypertension in those with chronic kidney 
disease (CKD) not only slows progression of renal dam-
age but reduces the risk of cardiovascular disease.
Achieving blood pressure (BP) control in CKD may be 
difficult, often requiring a combination of antihyperten-
sive medications as well as lifestyle modifications.
One size does not fit all—an understanding of the exist-
ing evidence is vital in order to deliver personalised 
management and achieve BP targets.
1 Introduction
Chronic kidney disease (CKD) affects 10–15% of the pop-
ulation worldwide and its prevalence is increasing [1, 2]. 
CKD is defined as the presence of reduced kidney function 
(an estimated glomerular filtration rate [eGFR] < 60 mL/
min/1.73 m2 [3]) or kidney damage (often indicated by 
the presence of proteinuria) for ≥ 3 months duration [4]. 
Hypertension, defined by the European Society of Cardiol-
ogy and the European Society of Hypertension (ESC/ESH) 
as a blood pressure (BP) of ≥ 140/80 mmHg affects ~ 30% 
of the general adult population and up to 90% of those with 
CKD [5, 6].
Hypertension is both a cause and effect of CKD and 
contributes to its progression [7–9]. As eGFR declines, 
the incidence and severity of hypertension increase [5]. 
Additionally, hypertension and CKD are both independ-
ent risk factors for cardiovascular disease (CVD). When 
both exist together the risks of CVD morbidity and mortal-
ity are substantially increased [10]. For those with stage 3 
(eGFR 30–59 mL/min/1.73 m2) or stage 4 (eGFR 15–29 mL/
min/1.73 m2) CKD, defined according to the Kidney Dis-
ease: Improving Global Outcomes (KDIGO) guidelines [4], 
the risk of death due to CVD is higher than the risk of pro-
gression to end-stage renal disease (ESRD) (eGFR < 15 mL/
min/1.73 m2) [11, 12]. Importantly, from a therapeutic 
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perspective, lowering BP can slow eGFR decline, delay 
progression to ESRD, and reduce the incidence of CVD in 
this patient group [13, 14].
2  Pathogenesis of Hypertension in Chronic 
Kidney Disease (CKD)
A number of mechanisms contribute to the development 
of hypertension in CKD and these influence its manage-
ment (Fig. 1). Increase in sympathetic tone, brought about 
by afferent signals generated by functionally declining 
kidneys, contributes to the development of hypertension 
in CKD [15]. As eGFR declines there is an upregulation 
of the renin–angiotensin–aldosterone system (RAAS) 
which promotes salt and water retention [16]. This is 
compounded by an increased salt sensitivity of BP [17]. 
Endothelial dysfunction is characteristic of advanced CKD 
(eGFR < 30 mL/min/1.73 m2) and its association with 
hypertension is well-established [18]. Increased arterial 
stiffness is also seen throughout the spectrum of CKD 
[19], is implicated in the development of hypertension 
[20], and is an independent risk factor for CVD events 
[21]. Once hypertension has developed, several factors, 
including increased oxidative metabolism, with resultant 
relative renal hypoxia, may drive further progression of 
BP and CKD [22, 23].
In health, BP demonstrates a nocturnal dip of ~ 10 to 
20%. This is controlled by several factors including diur-
nal variations in autonomic function, salt excretion and 
the RAAS [24]. Dysregulation of these systems in CKD 
leads to a non-dipping or even rising nocturnal BP, which 
is associated with increased CVD morbidity and mortality 
and risk of CKD progression [25, 26].
Upregulation of RAAS
CKD
Proteinuria No proteinuria
ACEi or ARB 
+/- CCB 
Hypertension and 
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Fig. 1  Pathogenesis and management flow-chart of hypertension in 
chronic kidney disease. ACEi angiotensin converting enzyme inhibi-
tor, ARB angiotensin II receptor antagonist (blocker), CCB calcium 
channel antagonist (blocker), CKD chronic kidney disease, RAAS 
renin–angiotensin–aldosterone system
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3  Measurement of Blood Pressure (BP) 
in CKD
For management of hypertension to be effective, accurate 
BP measurements are essential. In practice, the treat-
ment of hypertension is often based on clinic or office BP 
recordings [27]. These may be inaccurate due to lack of 
repeat measurements, diurnal variation in BP and white-
coat hypertension [28]. Thus, this snapshot of BP may not 
accurately define the clinical problem. Different pheno-
types of hypertension are recognised and associated with 
varying degrees of CVD risk (Table 1). In order to iden-
tify these and institute treatment accordingly, more robust 
methods of measuring BP should be used.
24-Hour ambulatory BP monitoring (ABPM) provides 
a more accurate depiction of BP phenotype and is a better 
predictor of CVD events in those with CKD than clinic 
readings [29]. 24-Hour ABPM also allows assessment of 
the diurnal variation in BP. Home BP monitoring is an 
alternative strategy that is less resource intensive. Those 
who obtain home readings demonstrate better overall BP 
control than those who do not [30]. Current hypertension 
guidelines reflect this, with the 2017 American College 
of Cardiology (ACC) guidelines supporting out-of-office 
BP measurement to confirm the diagnosis of hyperten-
sion and for titration of BP-lowering medication in all 
patients [31]. To ensure accuracy, only validated home BP 
devices should be used [32]. ACC guidelines also describe 
the anticipated relationship between clinic and out-of-
clinic BP measurements, suggesting that a clinic BP of 
140/90 mmHg equates approximately to a home BP value 
of 135/85 mmHg and to daytime and nocturnal ABPM 
values of 135/85 and 120/70 mmHg, respectively [31].
4  Proteinuria
Proteinuria is an important marker of renal damage and 
is incrementally and independently associated with CKD 
progression and incident CVD [10]. Quantification of pro-
teinuria allows stratification of this risk and can also be used 
as a marker of response to treatment (Table 2). The most 
practical way to measure proteinuria is with a protein-to-
creatinine ratio (PCR) obtained from a spot urine sample. 
An albumin-to-creatinine ratio (ACR) is more accurate when 
protein leak is minimal, with an ACR value of ≥ 3 mg/mmol 
sufficient for a diagnosis of CKD regardless of eGFR [34]. 
Table 1  Association of hypertension phenotype with all-cause mortality (adapted from Banegas et al. [33] using Cox regression model)
Values represent patients on treatment and without chronic kidney disease
ABPM ambulatory blood pressure monitoring, BP blood pressure, CI confidence interval
a Normal clinic BP defined as < 140/90 mmHg. Normal 24-h BP defined as < 130/80 mmHg
BP Phenotype Descriptiona All-cause mortality 
hazard ratio (95% 
CI)
Normotension Normal clinic BP, normal 24-h ABPM Reference
White-coat hypertension High clinic BP, normal 24-h ABPM 1.79 (1.38–2.32)
Sustained hypertension High clinic BP, high 24-h ABPM 1.80 (1.41–2.31)
Masked hypertension Normal clinic BP, high 24-h ABPM 2.83 (2.12–3.79)
Table 2  Quantification of proteinuria (adapted from Kidney Disease: Improving Global Outcomes 2012 chronic kidney disease guidelines [4])
Relationship between measurement methods are not exact and will depend on multiple variables
ACR albumin-to-creatinine ratio, PCR protein-to-creatinine ratio
Quantification method Normal or mildly increased Moderately increased Severely increased Nephrotic range
Dipstick Negative to trace Trace to + + or greater +++ or greater
ACR 
 mg/mmol < 3 3–30 > 30 > 220
 mg/g < 30 30–300 > 300 > 2200
PCR
 mg/mmol < 15 15–50 > 50 > 300
 mg/g < 150 150–500 > 500 > 3000
24-h urinary protein (g/day) < 0.15 0.15–0.5 > 0.5 > 3
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Total daily proteinuria can be obtained via a 24-h urine col-
lection or extrapolated from a PCR or ACR measurement 
[35]. Although 24-h urine collection remains the gold stand-
ard method for quantification of proteinuria, susceptibility 
to patient and sampling errors can lead to inaccuracies [36]. 
Several studies have demonstrated equivalency or superior-
ity of ACR or PCR over 24-h albumin or protein excretion 
in predicting CKD progression [37, 38].
BP reduction reduces proteinuria, which slows eGFR 
decline and reduces CVD [39]. More intense BP reduc-
tion (a target systolic BP < 120 mmHg) may offer greater 
renoprotection in those with significant proteinuria (> 1 g/
day; PCR > 100 mg/mmol, ACR > 70 mg/mmol) than in 
those without proteinuria [40, 41]. In addition to its anti-
hypertensive effects, the impact of a drug on proteinuria 
is an important consideration when managing hypertension 
in CKD. In particular, RAAS blockade appears to offer a 
BP-independent reduction in proteinuria [42]. Thus, these 
medications are considered first-line therapy for those with 
proteinuric CKD [31].
5  Goals of BP Reduction and BP Targets
Guidelines offer the treating clinician a rapid, evidence-
based, expert opinion regarding the management of certain 
conditions. Often criticised for a lack of flexibility, however, 
they are seen by some as unhelpful due to the complexities 
involved in clinical decision-making. Guidelines governing 
the management of patients with CKD are relatively few in 
relation to other conditions of similar prevalence. This may, 
in part, reflect the relative dearth of high-quality clinical 
trials in CKD. Despite this, guidelines outlining optimal 
treatment for CKD patients with hypertension are important, 
particularly as many of these patients are jointly managed 
in primary care.
In their 2017 guidelines, the ACC recommended that 
all adults with hypertension and CKD should be treated 
to a target BP of < 130/80 mmHg regardless of proteinu-
ria [31]. The National Institute for Health and Care Excel-
lence (NICE) and UK Renal Association suggest a more 
conservative target of < 140/90 mmHg, provided proteinuria 
is < 1 g/day [43, 44]. In the presence of greater degrees of 
urinary protein leak this target is revised to < 130/80 mmHg. 
KDIGO guidance also suggests a lower BP target for those 
with significant proteinuria, although it deploys a cut-off 
of > 300 mg/day [45]. The 2018 ESC/ESH guidelines sug-
gest a target systolic BP of < 140 mmHg regardless of pro-
teinuria [46]. To understand the differences between these 
guidelines one must consider the evidence used to create 
them (Fig. 2).
6  BP Control for Renal Protection
The Modification of Diet in Renal Disease (MDRD) study 
was the first randomised trial to investigate the effect of 
standard (target mean arterial pressure [MAP] 107 mmHg) 
versus intensive (target MAP 92 mmHg) BP control on the 
rate of eGFR decline in a US population with CKD (eGFR 
13–55 mL/min/1.73 m2). In patients with baseline proteinu-
ria > 1 g/day intensive BP control did slow the rate of eGFR 
decline when compared with standard BP control. However, 
no such benefit was seen in those without proteinuria [40]. 
1994 2002 2005 2010 2015
MDRD
Interventions: Target MAP 107 vs 92 mmHg
Participants: eGFR 13–55 mL/min/1.73 m2
Follow-up: 840 patients, mean 2.2 years
Results: Slowed eGFR decline in intensive group 
only if baseline proteinuria > 1 g/day
AASK
Interventions: MAP 102–107 vs 97 mmHg
Participants: eGFR 20–65 mL/min/1.73 m2, non-
diabetic
Follow-up: 1094 patients, minimum 3 years
Results: Slowed eGFR decline in intensive group 
only if baseline proteinuria > 1 g/day
REIN-2
Interventions: DBP < 90 vs BP < 130/80 mmHg 
with addition of CCB
Participants: Proteinuria > 1 g/day, eGFR
< 70 mL/min/1.73 m2, non-diabetic, on ACEi
Follow-up: 335 patients, median 1.6 years
Results: No difference in time to ESRD
ACCORD
Interventions: SBP < 140 vs < 120 mmHg
Participants: T2DM, eGFR > 60 mL/min/1.73 m2
Follow-up: 4733 patients, mean 4.7 years
Results: No difference in risk of death from CVD, 
but decreased rate of stroke in intensive group
SPRINT
Interventions: SBP < 140 vs < 120 mmHg
Participants: eGFR > 20 mL/min/1.73 m2, non-
diabetic, elevated CVD risk
Follow-up: 9361 patients, median 3.3 years
Results: Decreased CVD and death in intensive 
group
Renoprotection
Cardioprotection
Fig. 2  Timeline of landmark randomised trials comparing standard 
with intensive blood pressure control. ACEi angiotensin converting 
enzyme inhibitor, BP blood pressure, CCB calcium channel antago-
nist (blocker), CVD cardiovascular disease, DBP diastolic blood pres-
sure, eGFR estimated glomerular filtration rate, ESRD end-stage renal 
disease, MAP mean arterial pressure, MDRD Modification of Diet in 
Renal Disease, SBP systolic blood pressure, T2DM type  2 diabetes 
mellitus
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In 2002, AASK (African American Study of Kidney Disease 
and Hypertension) mirrored these results in a non-diabetic 
African American population with a GFR of 20–65 mL/
min/1.73 m2. In this study, 1094 patients were randomised 
to receive either standard (MAP 102–107 mmHg) or inten-
sive (MAP 97 mmHg) BP control with a minimum follow-
up period of 3 years. Again, only patients with baseline 
proteinuria > 1 g/day demonstrated slowing of CKD with 
intensive BP control [41, 47]. The REIN-2 (Ramipril Effi-
cacy in Nephropathy-2) study examined whether intensive 
BP control with the addition of a dihydropyridine calcium 
channel antagonist (blocker) (CCB) to those already estab-
lished on an angiotensin converting enzyme (ACE) inhibitor 
was superior to standard BP control with an ACE inhibi-
tor alone. The study included those with CKD and baseline 
proteinuria > 1 g/day. The addition of a CCB did reduce BP; 
however, this did not translate into improved renoprotection 
[48]. Guidelines published in the wake of these landmark 
studies reflected these results, suggesting lower targets only 
for those with significant proteinuria. However, these stud-
ies did not consider the potential benefits of intensive BP 
control on cardiovascular endpoints.
7  BP Control for Cardiovascular Protection
The ACCORD (Action to Control Cardiovascular Risk in 
Diabetes) study examined the effect of intensive (target 
systolic BP < 120 mmHg) versus standard (target systolic 
BP < 140 mmHg) BP control on cardiovascular outcomes 
(myocardial infarction [MI], stroke or death from CVD) 
in patients with type 2 diabetes mellitus and normal renal 
function (serum creatinine < 133 μmol/L) [49]. Despite a 
sustained difference in attained BP between the standard and 
intensive treatment groups, the risk of death from CVD did 
not differ significantly. There was, however, a reduced risk 
of stroke with intensive BP control.
Published in 2015, SPRINT (Systolic Blood Pressure Inter-
vention Trial) compared a systolic BP target of < 140 mmHg 
with a more intensive systolic goal of < 120 mmHg in 9361 
non-diabetic patients at elevated CVD risk (defined as the 
presence of CVD, CKD, age > 75 years, or 10-year CVD risk 
≥ 15%) [50]. The intensive treatment group demonstrated a 
statistically significant reduction in the primary outcome, a 
composite of MI, acute coronary syndrome, stroke, heart fail-
ure or death from CVD. A reduction in the secondary outcome 
of death from any cause was also significant. The effect size 
was so large the trial was stopped prematurely after three of its 
projected 5-year duration. In those with CKD (n = 2646, mean 
GFR 47.9 mL/min/1.73 m2) intensive BP control reduced all-
cause mortality with an effect size similar to that seen in the 
overall cohort [14]. Despite this, there was no effect on renal 
outcomes, including the rate of eGFR decline. Unfortunately, 
those with eGFR < 20  mL/min/1.73  m2 and/or proteinu-
ria > 1 g/day were excluded from SPRINT, as were those with 
diabetes, who account for up to 45% of CKD in the developed 
world [51]. Nevertheless, SPRINT suggests that intensive BP 
control reduces CVD morbidity and mortality in those with 
CKD. Of note, extended follow-up data now available from 
both the MDRD and AASK studies also suggest a long-term 
survival benefit from intensive BP lowering despite no change 
in the rate of CKD progression [52, 53].
It should be noted that the method of BP measurement 
used may have a significant impact on the outcome of 
any trial. In SPRINT, BP was measured after participants 
were seated in a quiet room for 5 min with no distractions. 
SPRINT BPs may, therefore, not be directly comparable to 
our clinic BPs, which are likely to be higher. This may be 
why such a low target BP was found to be beneficial. Nota-
bly, the risk of developing acute kidney injury (AKI) was 
increased in the intensive treatment group. Additionally, 
in those with normal renal function at baseline, the risk of 
developing CKD during the study was higher with intensive 
treatment. An analysis by Zhang et al. [54] has investigated 
whether these changes represent true renal injury by examin-
ing biomarkers of kidney damage in this cohort. They found 
that the intensive BP lowering used in SPRINT was associ-
ated with a decrease in kidney damage biomarkers, includ-
ing ACR, anti-chitinase-3-like protein 1 and uromodulin, 
suggesting that benign alteration in renal blood flow, rather 
than pathological processes, may be responsible for the 
changes in eGFR observed [54].
The available evidence does not provide a clear consen-
sus regarding the optimal BP target in CKD. Accordingly, 
guidelines vary. The 2017 ACC guidelines employed the 
results of SPRINT as the basis for a more intensive BP 
target. However, the 2018 ESC/ESH guidelines have not 
adopted this more intensive approach. Perhaps this could be 
interpreted as a prioritisation of cardiovascular protection 
over renoprotection by the Americans, and vice versa by the 
Europeans. Examining the available evidence allows under-
standing of the rationale behind these decisions and thus a 
basis on which to create individualised treatment plans that 
take into account CVD risk, rate of projected eGFR decline, 
co-morbidities and other patient characteristics. BP goals 
are likely to change as an individual ages or develops more 
advanced disease. The management of BP in CKD should 
therefore be considered a dynamic process.
8  Achieving BP Targets
Achieving BP targets is challenging. SPRINT demonstrated 
that, despite intensive input including monthly medication 
reviews, > 50% of those in the intensive treatment group 
failed to achieve the target systolic BP [50]. Results in those 
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with CKD suggest that it may be even more challenging to 
achieve BP goals than in the general hypertension population 
[55]. Despite treatment with non-pharmacological interven-
tions and multiple antihypertensive agents, the majority of 
CKD patients fail to reach target BP [56].
9  Non‑Pharmacological Treatment
There are a number of non-pharmacological treatments 
for hypertension in the context of CKD. A study by Slag-
man et al. [57] found that, in those already established on 
RAAS blockade, reducing dietary sodium intake to a target 
of < 50 mmol/day (~ 3 g/day of salt) decreased systolic BP by 
a further ~ 10 mmHg. A restriction to a target < 100 mmol/
day (~ 6 g/day of salt) has also demonstrated a reduction 
in proteinuria by ~ 25%, an effect that is unlikely to be 
explained by BP reduction alone [58]. There are some in 
whom the effects of dietary sodium have little impact on 
BP. However, as GFR declines, the sensitivity of BP to die-
tary sodium load increases [17]. In practice, dietary sodium 
restriction can be difficult to achieve. Urinary sodium meas-
urements by Slagman et al. [57] demonstrated that despite 
regular counselling sessions, the mean dietary sodium intake 
in the group targeting < 50 mmol/day was 106 mmol/day. In 
those without dietary restriction the intake was 186 mmol/
day. Acknowledging personal dietary preferences and setting 
realistic goals (< 100 mmol/day of sodium) under the super-
vision of a dietitian may improve the likelihood of achieving 
meaningful and sustained dietary changes [59].
Weight loss is effective in reducing BP and proteinuria 
and may slow CKD progression [60]. In overweight patients 
(body mass index [BMI] > 27 kg/m2) with CKD and pro-
teinuria (> 1 g/24 h), a mean weight loss of ~ 4% can reduce 
proteinuria by ~ 30% [61]. The benefits of a multidiscipli-
nary approach have also been demonstrated in CKD. A sys-
tematic review by Santschi and colleagues [62] has shown 
improved attainment of BP goals in hypertensive patients 
following the introduction of community pharmacists. In 
the MASTERPLAN (Multifactorial Approach and Superior 
Treatment Efficacy in Renal Patients with the Aid of Nurse 
Practitioners) study conducted in the Netherlands, special-
ised nursing care clearly improved the management of CVD 
risk factors, including BP, at 1 and 2 years in patients with 
stage 3–4 CKD [63].
10  Pharmacological Treatment
Despite the benefits of non-pharmacological interventions in 
CKD, antihypertensive medications are usually also required 
[56]. As well as direct BP-lowering effects, certain pharma-
cological therapies provide additional renoprotective and/or 
cardioprotective action, which may be independent of their 
BP-lowering effects [47]. The choice of drug should there-
fore consider the balance of risk reduction required by the 
individual. Combination drug therapy is frequently needed 
to achieve BP targets [64], and thus the risks of polyphar-
macy need also be considered.
10.1  Renin–Angiotensin–Aldosterone System 
Blockade
ACE inhibitors and angiotensin II receptor antagonists 
(blockers) (ARBs) have both cardioprotective and renopro-
tective properties and are therefore of particular value in 
patients with CKD [42]. RAAS blockade can reduce systolic 
BP by ~ 20 mmHg in patients with hypertension and CKD 
[55]. This is similar to the BP reduction offered by CCBs 
and diuretics. Importantly, however, these agents offer a BP-
independent reduction in proteinuria in both diabetic and 
non-diabetic CKD and are therefore generally accepted as 
first-line management of hypertension in patients with pro-
teinuric CKD [39, 64–66].
In those with non-proteinuric CKD the superior reno-
protective effect of RAAS blockade has recently been ques-
tioned. A systematic review carried out by Casas and col-
leagues [67] demonstrated that the improved renal outcomes 
associated with RAAS blockade are most likely due to a 
BP-lowering effect only, and could therefore be mirrored 
by other antihypertensives if the same reduction in BP was 
achieved. Consequently, although ACE inhibitors may be 
used as first-line agents in those with hypertension and non-
proteinuric CKD, CCBs and thiazide or thiazide-like diuret-
ics should also be considered as alternative first-line choices 
in this population [46].
In up to 50% of patients chronic ACE inhibition leads 
to angiotensin  II reactivation with subsequent blunt-
ing of the efficacy of RAAS blockade. It has therefore 
been hypothesised that the addition of an ARB to those 
already established on ACE inhibition might improve 
cardiovascular and renal outcomes. ONTARGET (Ongo-
ing Telmisartan Alone and in Combination with Ramipril 
Global Endpoint Trial) aimed to answer this question in 
patients at high risk of CVD [68]. 25,620 patients were 
randomised to either ACE inhibitor, ARB or combination 
therapy with both agents and followed up for a median 
period of 56 months. Combination therapy was associated 
with an increased incidence of adverse effects with no sig-
nificant reduction in the primary outcome of death from 
CVD, MI, stroke or heart failure. The VA NEPHRON-D 
(Veterans Affairs Nephropathy in Diabetes) study exam-
ined renal outcomes in a cohort of diabetic patients with 
CKD [69]. Again, combination therapy with an ACE 
inhibitor and ARB led to an increase in adverse events 
without a significant reduction in the primary endpoint of 
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progression of CKD, ESRD or death. Combination ther-
apy with both an ACE inhibitor and ARB is therefore no 
longer advised in those with CKD. Notably, these studies 
included subjects at high risk of renal vascular disease, in 
whom GFR is to some extent dependent on a functional 
RAAS. In patients with conditions such as immunoglobu-
lin A (IgA) nephropathy, the leading primary glomerular 
cause of ESRD in the USA, dual angiotensin blockade 
reduces proteinuria to a greater extent than monotherapy. 
These patients are younger and at lower cardiovascular 
risk than those in VA NEPHRON-D and ONTARGET. 
Whether this translates to a greater cardiovascular and 
renal benefit is currently unclear.
Potential problems associated with RAAS blockade 
include hyperkalaemia and the development of AKI. A 
rise in serum creatinine is often seen after initiation of 
RAAS blockade due to a reduction in intraglomerular 
pressure [70]. The RENAAL (Reduction in End Points in 
Noninsulin-Dependent Diabetes Mellitus with the Angio-
tensin II Antagonist Losartan) study randomised 1513 
patients with diabetic nephropathy (defined as proteinu-
ria > 0.5 g/day or serum creatinine 115–265 μmol/L) to 
losartan or placebo. The losartan group demonstrated a 
greater fall in eGFR during the first 3 months of treatment 
(– 2.3 vs – 1.6 mL/min/1.73 m2) [39, 71]. The significance 
of this transient fall in eGFR is unclear. Observational 
data from the UK primary care setting have demonstrated 
adverse cardiorenal outcomes in those with an initial 
eGFR decline following initiation of an ACE inhibitor or 
ARB [72]. In contrast, after a mean follow-up period of 
3.4 years, RENAAL patients randomised to losartan had 
a slowed rate of eGFR decline compared with placebo 
regardless of initial rate of decline. Current guidelines 
suggest that a rise in serum creatinine of up to 30% with 
subsequent stabilisation should be accepted following 
initiation of RAAS blockade as this is likely to confer 
longer-term renoprotection [43].
Further uncertainty exists regarding the use of RAAS 
blockade in those with advanced CKD (eGFR < 30 mL/
min/1.73 m2) as this population has been largely excluded 
from major randomised trials. An observational study by 
Ahmed et al. [73] demonstrated a significant increase in 
eGFR when RAAS blockade was withdrawn in a cohort 
of patients with advanced CKD in the UK, which in 
some cases prolonged time to starting renal replacement 
therapy. As a consequence, a national, multicentre, ran-
domised trial of ACE inhibitor/ARB withdrawal (STOP-
ACEi) in advanced CKD has begun [74]. Until results 
from this trial are available, the question of whether or 
not to initiate or continue RAAS blockade in those with 
advanced CKD remains uncertain.
10.2  Diuretics
Volume overload, often subclinical, affects up to 50% of 
people with CKD and is an independent risk factor for CVD 
[75]. Diuretic therapy can reduce volume expansion and has 
been shown to improve left ventricular mass index and arte-
rial stiffness in those with CKD [76, 77]. Thus, diuretics are 
frequently used as part of combination drug therapy in CKD 
and offer antihypertensive and cardioprotective effects [76].
In non-proteinuric CKD, monotherapy with a thiazide 
(such as bendroflumethiazide) or a thiazide-like diuretic 
(such as indapamide) may have a role and should be con-
sidered as a potential for first-line therapy [43]. Treatment 
with a diuretic may also reverse the loss of physiological 
nocturnal dip in BP described in CKD [78]. Loop diuretics 
(such as furosemide) are valuable, although higher doses 
are often required in those with a lower eGFR as the tubular 
mechanism of action of these drugs relies first on glomerular 
filtration. The combination of a loop and thiazide diuretic 
is particularly powerful, and care should be taken to avoid 
fluid depletion. Diuretics should generally be avoided in 
patients with polycystic kidney disease due to accelerated 
cyst growth and loss of excretory function associated with 
their use [79].
Mineralocorticoid receptor antagonists (blockers) (such 
as spironolactone) effectively reduce BP in CKD but run the 
risk of exacerbating hyperkalaemia [80]. These agents have 
been demonstrated to improve systolic and diastolic function 
in early CKD and therefore may be of particular value in 
patients with concomitant left ventricular dysfunction [81]. 
It is unclear whether this effect is due to BP lowering alone. 
In order to answer this question, a randomised study com-
paring spironolactone with the thiazide-like diuretic chlo-
rthalidone in patients with CKD stage 3 has been completed 
(SPIRO-CKD [Spironolactone in Chronic Kidney Disease]) 
and results are awaited [82]. In hypertensive patients without 
CKD, spironolactone is more effective than bisoprolol or 
doxazosin at reducing BP when used as a fourth-line add-on 
therapy [83].
10.3  Calcium Channel Antagonists (Blockers)
Both dihydropyridine and non-dihydropyridine CCBs are 
useful in the management of hypertension in CKD. Dihydro-
pyridine CCBs (such as amlodipine) can be used as first-line 
therapy in non-proteinuric CKD, either alone or in combi-
nation. In proteinuric CKD their effect is inferior to RAAS 
blockade [41]. However, the addition of a dihydropyridine 
CCB to proteinuric patients with established RAAS block-
ade improves BP control without worsening proteinuria [39]. 
This has been reflected in the recently updated ESC/ESH 
guidelines which advocate combination therapy with an 
ACE inhibitor and CCB as first-line therapy in proteinuric 
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patients [46]. Non-dihydropyridine CCBs (such as vera-
pamil) have a superior effect on proteinuria reduction and 
are as effective as dihydropyridine CCBs in terms of BP 
control [84].
The ACCOMPLISH (Avoiding Cardiovascular Events 
through Combination Therapy in Patients Living with Sys-
tolic Hypertension) trial evaluated combination therapy with 
amlodipine and an ACE inhibitor versus hydrochlorothiazide 
and an ACE inhibitor in reducing CVD mortality in those 
with hypertension and at high risk of CVD (defined as the 
presence of diabetes, left ventricular hypertrophy, peripheral 
arterial disease, CKD or history of CVD) [85]. This mul-
ticentre, double-blind, randomised trial also included the 
prespecified endpoint of progression of CKD, defined as a 
doubling of baseline serum creatinine or reaching ESRD. 
The trial was terminated early due to superior efficacy of 
amlodipine and ACE inhibitor on CVD mortality. Notably, 
there was also a significantly lower risk of CKD progression 
in the amlodipine group that was independent of attained 
BP values. This suggests that the addition of amlodipine to 
ACE inhibitor therapy does exert an additional renoprotec-
tive effect over the addition of a thiazide diuretic in this at-
risk group. Although generally well-tolerated, CCBs have 
the potential to worsen peripheral oedema, something that 
can be particularly troublesome for those with CKD [85].
10.4  β‑Blockers
β-Blockers (β-adrenoceptor antagonists) effectively reduce 
BP in CKD due to their effect on the dysregulated sym-
pathetic nervous system [15]. The cardioprotective benefits 
of these drugs are well-established [86, 87] and therefore 
they are particularly advantageous in those with CKD. 
In animal studies, β-blockers also display renoprotective 
effects, including a reduction in the development of inter-
stitial fibrosis following renal injury [88, 89]. Prospective 
and observational studies have demonstrated survival benefit 
from β-blocker therapy compared with placebo in patients 
with CKD [90, 91]. Despite this, β-blockers are used less 
frequently in those with than in those without CKD [92]. 
Underuse in patients with CKD may be partially explained 
by concerns regarding glycaemic control, reduced renal 
excretion and systemic accumulation [93, 94]. Although 
these are potential risks with certain classes of β-blockers, 
these drugs can be safely used in all degrees of renal impair-
ment. Dosing adjustments may be required, and hepatically 
excreted β-blockers and those with additional vasodilatory 
properties (such as carvedilol) are likely to be of particular 
value [95]. Direct comparisons with ACE inhibitors have 
shown β-blockers to offer inferior renoprotection [96, 97]. 
The AASK study did, however, demonstrate lower rates of 
ESRD and death in CKD patients treated with metoprolol 
versus amlodipine [47]. β-Blockers should therefore be 
considered as useful additions in those with established 
RAAS blockade, particularly when overt CVD coexists.
10.5  α‑Blockers
Peripherally acting α-blockers (α-adrenoceptor antagonists; 
such as doxazosin) are commonly used as part of combina-
tion therapy for the management of hypertension in CKD. 
This may be due to a pharmacokinetic profile that is undis-
turbed by declining eGFR in addition to favourable effects 
on glycaemic control [98]. Several studies have demon-
strated their efficacy as add-on therapy in the management 
of hypertension in CKD [99, 100]. α-Blockers should not, 
however, be considered for first-line therapy, as they are 
less effective than other agents for reducing the incidence 
of CVD [101].
10.6  Chronotherapy
As the diurnal variation of BP can be influenced by timing 
of antihypertensive medications, it has been hypothesised 
that evening dosing could reverse the non-dipping nocturnal 
BP seen in CKD. A study by Hermida and colleagues [102] 
explored the effects of nocturnal antihypertensive dosing in 
661 patients with CKD by assigning participants to take all 
antihypertensive medication upon wakening or to take one 
or more antihypertensive at night. After a median follow-up 
period of 5.4 years the nocturnal dosing group had signifi-
cantly better BP control and lower incidence of CVD death, 
MI and stroke than those who took all medications in the 
morning. Chronotherapy would therefore seem to be one of 
the more straightforward methods of achieving improved 
outcomes for those with hypertension and CKD.
10.7  Adherence
Despite the risks of CKD progressing to ESRD and patients 
requiring dialysis and/or transplantation, adherence to ther-
apy is no better in those with CKD than in those without 
[103]. Adherence improves as CKD advances but deterio-
rates again as patients start dialysis [104]. Studies exam-
ining the reasons for non-compliance in those with CKD 
highlight the importance of communication and perceived 
benefit of the therapies in question [105]. Pill burden, drug 
interactions and adverse effects are also important. Antihy-
pertensive regimens should therefore be simplified wherever 
possible, with consideration given to the quantity, timing 
and formulation of interventions. Continuity of care may 
also have an impact and, where possible, attempts should 
be made to allow patients to see the same clinician at each 
visit, something that has been demonstrated to improve out-
comes [106].
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11  Managing Hypertension in the Context 
of Haemodialysis
The relationship between BP and CVD outcomes in 
patients undergoing haemodialysis is complex. In this 
cohort, a lower BP does not necessarily translate into 
improved survival, as it does in the general population 
and those with pre-dialysis CKD [107, 108]. Evidence to 
guide BP targets in this group is limited. In a study by 
Li and colleagues [108], 125,928 haemodialysis patients 
were grouped into different pre-dialysis systolic BP cat-
egories and observed over 3 years. The highest mortality 
was seen in those patients with a pre-dialysis systolic BP 
of < 120 mmHg. A higher pre-dialysis BP was protective, 
with the lowest mortality seen in those with a pre-dialysis 
systolic BP of 160–180 mmHg [108]. This ‘inverse epi-
demiology’ has been demonstrated previously, although 
remains poorly understood [109]. Changes in BP during 
haemodialysis may also predict adverse clinical outcomes. 
Retrospective data have demonstrated that intradialytic 
hypertension is associated with an increased 30-day mor-
tality and rate of hospitalisation [110].
The optimal way to measure BP in patients undergo-
ing haemodialysis is debatable. Large shifts in fluid and 
electrolytes mean pre- and post-dialytic BPs may dif-
fer significantly. Mayer et al. [111] utilised 24-h ABPM 
applied immediately before a dialysis session to examine 
the relationship between systolic BP and mortality in a 
haemodialysis cohort. During the 3-year follow-up period 
a U-shaped relationship between 24-h systolic ABMP 
and all-cause mortality was evident, demonstrating an 
increased risk of death for those with either very low or 
very high BP. Subgroup analysis demonstrated a linear 
relationship in those with and without CVD. In patients 
with CVD, a lower BP was associated with a higher risk 
of death. The opposite was true for those without CVD, 
explaining the overall U-shaped curve. This demonstrates 
the need for personalised BP treatment plans that incorpo-
rate co-morbidities in patients undergoing haemodialysis. 
CVD risk calculators have long been available to predict 
the risk of CVD events for individual patients. Not only do 
novel risk calculators such as  QRISK®3 now include those 
with CKD, but several risk calculators designed for use in 
the haemodialysis population have now been developed 
and validated [112, 113].
Hypertension in patients undergoing haemodialysis may 
be largely driven by sodium and water overload. However, 
hypertension often persists despite aggressive ultrafiltra-
tion [114]. All classes of antihypertensive may be used, 
although data governing this are limited. Use of β-blockers 
is particularly attractive as they mitigate some of the 
arrhythmogenic effects of dialysis and reduce arterial 
stiffness and left ventricular hypertrophy, both of which 
are accelerated in ESRD [95, 115]. Choice of β-blocker 
remains contentious, in part due to variable degrees of 
drug clearance during haemodialysis [95].
12  Managing Hypertension Following 
Kidney Transplantation
As in haemodialysis, there are currently no randomised 
clinical trials exploring how best to manage hypertension 
following kidney transplantation. Hypertension is common 
post-transplant, with multiple factors contributing to its 
development (Fig. 3). More than 90% of recipients of a kid-
ney transplant receiving a calcineurin inhibitor (CNI)-based 
immunosuppression regimen will be hypertensive post-
transplant [116]. BP is also more likely to be uncontrolled, 
with ~ 50% failing to achieve a systolic BP < 140 mmHg at 
1 year [117]. Higher BP is associated with poorer graft out-
comes and greater CVD risk, which is the leading cause of 
death following kidney transplant [118–120]. A retrospec-
tive study of 1666 kidney transplant recipients demonstrated 
a ~ 5% increased risk of graft failure and death with every 
10 mmHg rise in systolic BP [117]. Broader cardioprotection 
including lipid-lowering and antiplatelet therapy is likely to 
be beneficial in most patients [121].
Choice of antihypertensive agent will depend on several 
factors, including time from transplantation, concomitant 
prescriptions including immunosuppression, and co-mor-
bidities. Historically, RAAS blockade has been avoided in 
the early post-transplant period due to the potential for a 
transient rise in serum creatinine at this precarious time. 
Despite this, a systematic review by Jennings and Taber 
[122] has suggested that early initiation of RAAS blockade 
(within 12 weeks post-transplant) improves left ventricu-
lar hypertrophy and proteinuria at 1 year without causing 
a fall in eGFR. Whether initiated early or not, these agents 
are considered to be important following renal transplanta-
tion due to the increased risk of CVD in this group [123]. 
However, there remains uncertainty regarding post-trans-
plant renoprotection. A study by Knoll et al. [124] aimed to 
address this uncertainty by examining the effect of ramipril 
versus placebo in 212 transplant recipients with proteinuria 
at least 3 months post-transplant. After a follow-up period 
of 48 months, ramipril did not lead to a significant reduc-
tion in doubling of serum creatinine, ESRD or death. This 
uncertainty is reflected in low rates of ACE inhibitor use in 
this group, with as few as 30% of patients with CVD and/or 
diabetes receiving RAAS blockade 6 months post-transplant 
[121].
CNIs such as tacrolimus, which form the mainstay of 
post-transplant immunosuppression, cause afferent arteri-
olar vasoconstriction. There is some evidence to suggest 
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that dihydropyridine CCBs confer particular benefit in those 
treated with CNIs due to their ability to cause afferent arte-
riolar vasodilatation in this context [125]. Non-dihydropyr-
idine CCBs interfere with CNI metabolism, necessitating 
closer monitoring of drug levels [126].
13  Future Directions
As populations live longer and the prevalence of diabetes 
increases, the global burden of CKD is likely to grow [127]. 
Managing elderly patients with hypertension and CKD is 
therefore an area of significant importance. Results from 
studies of elderly hypertensives without CKD demonstrate 
significant reductions in heart failure, stroke and death from 
CVD when BP is controlled [128, 129]; however, evidence 
in those with CKD, a group at higher CVD risk, is lack-
ing. Future work should aim to enhance our understand-
ing of optimum BP targets in elderly patients with CKD for 
both cardio- and renoprotection. The STOP-ACEi trial may 
provide useful information regarding the specific merits of 
RAAS blockade in this group [74].
Improved survival of patients with several chronic dis-
eases has also led to an increased incidence of CKD in these 
groups. For example, the life expectancy of a 20-year-old 
patient starting antiretroviral therapy (ART) for HIV in the 
UK is now almost 70 years [130]. HIV is associated with an 
increased prevalence of both hypertension and CKD [131]. 
In those treated with ART aged > 50 years, more than 50% 
will be hypertensive, with an approximately four times 
higher prevalence of microalbuminuria than the general 
population [132]. Although the advent of ART has reduced 
the number of patients progressing to ESRD, there is still 
an excess mortality in those with ESRD secondary to HIV-
associated nephropathy [133]. Efforts to identify and control 
hypertension and renal dysfunction in this patient group are 
therefore critically important.
There remains an unmet need for therapeutic options 
capable of slowing progression of CKD and attenuat-
ing the associated CVD risk. Interest in sodium–glucose 
cotransporter 2 inhibitors (SGLT2i), such as empagliflo-
zin, has intensified following the EMPA-REG OUTCOME 
(BI 10773 [Empagliflozin] Cardiovascular Outcome Event 
Trial in Type 2 Diabetes Mellitus Patients) trial, which 
demonstrated significant slowing of CKD progression and 
a reduction in the composite outcome of death from CVD, 
non-fatal MI or non-fatal stroke in patients with type 2 
diabetes and high CVD risk randomised to empagliflozin 
versus placebo [134, 135]. Exploratory studies have also 
suggested benefit from endothelin receptor antagonists in 
reducing both BP and proteinuria in those with CKD [136]. 
Although larger randomised studies have shown limited anti-
hypertensive efficacy [137], DUET (Efficacy and Safety of 
Sparsentan [RE-021], a Dual Endothelin Receptor and Angi-
otensin Receptor Blocker, in Patients with Focal Segmental 
Glomerulosclerosis [FSGS]: A Randomized, Double-blind, 
Active-Control, Dose-Escalation Study) did demonstrate a 
reduction in proteinuria in patients with FSGS randomised 
to dual endothelin-A and angiotensin II receptor antagonists 
compared with ARB alone [138]. Phase III trials involv-
ing patients with both FSGS and IgA nephropathy are now 
underway. Direct renin inhibitors have shown promise in 
early studies but adequately powered, high-quality trials 
are required [139]. The prevalence of treatment-resistant 
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hypertension in CKD is a growing concern and the inclusion 
of this patient group in large-scale randomised outcome tri-
als may help to guide treatment [140, 141]. Interest in renal 
denervation for resistant hypertension has also been renewed 
following results from a proof-of-concept randomised trial 
[142]; however, significant doubt still exists as to whether 
this treatment is effective and safe in CKD.
Finally, there is a growing body of evidence to suggest 
that health literacy has a direct influence on outcomes in 
CKD [143]. As the global burden of this condition increases, 
targeting improvements in health literacy at both a local and 
national level may improve outcomes in this patient group. 
Practically, encouraging shared decision-making and patient 
involvement wherever possible might be a useful first step.
14  Conclusion
Lowering BP in CKD slows disease progression and reduces 
incident CVD. An understanding of the pathophysiological 
mechanisms leading to the development of hypertension in 
this patient group is useful in order to effectively target both 
endpoints. Existing guidelines do not offer a consensus on 
optimal BP targets but are created based on evidence favour-
ing interventions for either renoprotection, cardioprotection 
or both. Similarly, pharmacological therapies designed to 
achieve these targets offer different degrees of risk reduction 
based on patient characteristics. One size does not fit all, 
therefore, and an appreciation of what is achievable with BP 
reduction in CKD is key to making informed, individualised 
decisions.
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